Anti-MID2 / Midline 2

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. MID2 antibody detects E3 ubiquitin-protein ligase MID2 (also known as Midline-2 or FXY2), a microtubule-associated E3 ligase involved in cytoskeletal organization, cell polarity, and developmental morphogenesis. Encoded by the MID2 gene on chromosome Xq22.3, this protein belongs to the tripartite motif (TRIM) family of ubiquitin ligases, featuring a RING finger domain, B-box zinc-binding motifs, a coiled-coil region, and a C-terminal COS domain that binds microtubules. MID2 functions in ubiquitination of cytoskeletal and signaling proteins, coordinating cell structure and trafficking processes crucial for morphogenesis and neurodevelopment.In human cells, MID2 localizes along microtubules, at the centrosome, and in perinuclear regions. It associates with its close paralog MID1, with which it shares structural and functional similarities. Together, MID1 and MID2 regulate the stability of PP2A catalytic subunits and participate in tubulin network maintenance. MID2 expression is particularly high in brain, testis, and embryonic tissues, reflecting roles in neuronal migration and organ development. Mutations in MID2 have been associated with X-linked intellectual disability and developmental disorders affecting craniofacial and skeletal structures.The MID2 antibody is widely used in cell biology and developmental research to study microtubule organization, ubiquitination, and cell morphology. Western blot analysis detects a ~78 kilodalton band corresponding to full-length MID2, while immunofluorescence reveals filamentous staining patterns overlapping with microtubules. MID2 ubiquitinates several substrates involved in cytoskeletal remodeling and signaling, including MID1-associated proteins and small GTPase regulators. Through these activities, it influences cell polarity, division, and migration. In neurons, MID2 contributes to axon guidance and growth cone dynamics.Dysregulation of MID2 expression or mutation of its functional domains can lead to developmental abnormalities and neurological defects. Overexpression has been observed in certain cancers, where it may enhance cell motility and invasiveness through altered cytoskeletal signaling. The MID2 antibody provides a robust tool for investigating these pathways and identifying mechanisms of microtubule regulation in both normal and diseased states. NSJ Bioreagents supplies this antibody validated for its applications, supporting research into cytoskeletal dynamics, developmental disorders, and ubiquitin-dependent regulation.